263 related articles for article (PubMed ID: 11795345)
1. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Dickler MN; Norton L
Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
[TBL] [Abstract][Full Text] [Related]
2. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
3. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
4. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen to raloxifene and beyond.
O'Regan RM; Jordan VC
Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of breast cancer in the older patient.
Minton SE
Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer prevention with selective estrogen receptor modulators: a perspective.
Pritchard KI
Ann N Y Acad Sci; 2001 Dec; 949():89-98. PubMed ID: 11795385
[TBL] [Abstract][Full Text] [Related]
9. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
Vogel VG
Clin Interv Aging; 2008; 3(4):601-9. PubMed ID: 19281053
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
11. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
12. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
13. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
14. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
Zujewski J
Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
[TBL] [Abstract][Full Text] [Related]
15. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
16. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Vogel VG
Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer: implications for postmenopausal women.
Fabian CJ; Kimler BF
Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
19. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]